Colorectal Cancer Stage IV
Conditions
Brief summary
Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.
Detailed description
Patients affected by CLMs and trated with neoadjuvant systemic chemotherapy and then hepatectomy were reviewed with the intent to assess the occurrence of liver atrophy, which is a sign of liver dysfunction and a source of morbidity expecially in patients treated with major or extended hepatectomy. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. Then, we planned to review our cases with the above mentioned endpoint.
Interventions
PROCEDUREHepatectomy
Surgical removal of a part of the liver
Sponsors
Azienda Ospedaliero Universitaria Maggiore della Carita
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Consecutive patients with multiple CLMs treated with preoperative chemotherapy and parenchymal sparing surgery; * Only patients with available volumetry of the pre- and post-chemotherapy abdominal enhanced computed tomography (CT) images;
Exclusion criteria
* Patients who underwent preoperative PVE; * Patients treated by major hepatectomies; Patients treated with thermal ablation alone or in association with hepatic resection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative complications | From the date of surgery up to 90 days | Any adverse event after surgery |
Outcome results
None listed